Somerset Lifesciences Pays $4 Million Over Medicare Drug Coverage Claims

Somerset Lifesciences Inc. has agreed to pay $4 million to resolve common law claims that it caused Medicare Part D to pay for a generic eye drop that was no longer eligible for coverage. The drug, Olopatadine, is the generic version of the brand name eye drop Pataday Twice Daily Relief. Before February 2020, both were available only by prescription and were covered by Medicare. When the FDA approved over-the-counter sales of Pataday, federal rules generally require a generic drug’s label to match its brand name counterpart. Somerset was therefore required to change Olopatadine’s label from prescription-only to over-the-counter as well.

According to the Justice Department, Somerset did not make the change. It continued to label and sell Olopatadine as a prescription-only product, which caused Medicare to pay claims for a drug that retail customers could already buy without a prescription. Medicare does not cover drugs available over the counter. The government alleged that Somerset’s conduct caused Medicare to pay these claims by mistake and unjustly enriched the company. The settlement resolves those common law claims, and the allegations are not a determination of liability.

The case highlights a quieter form of healthcare fraud that does not involve kickbacks or fabricated bills. Instead, it turns on whether a product still qualifies for federal reimbursement, a question that depends on accurate labeling and timely compliance with regulatory changes. The government has emphasized that False Claims Act enforcement, along with tips and complaints from all sources, remains central to protecting federal healthcare programs. Whistleblowers with knowledge of improper billing or ineligible products can help identify these issues early.